Dyne Therapeutics Announces New Clinical Data from ACHIEVE

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - ...

Related Keywords

United States ,Amy Reilly ,John Cox ,Stacy Nartker ,Wildon Farwell ,Exchange Commission ,Dyne Therapeutics Inc ,Nasdaq ,Facebook ,European Medicines Agency ,Drug Administration ,Myotonic Dystrophy Health Index ,Linkedin ,Dose Dependent ,Mean Splicing Correction Across All Patients ,Muscle Strength ,Timed Function Tests ,Reported Outcomes ,Mean Unadjusted ,Mean Muscle Adjusted ,Dystrophin Expression ,Cohort Administered Monthly ,Higher Level ,Dystrophin Than Reported ,Weekly Administered Standard ,Functional Improvement ,Run Time ,Stride Velocity ,Safety Profiles ,Enrollment Complete ,Recent Regulatory Interactions ,Pursue Expedited Approvals ,Both Programs ,Registrational Pathways Expected ,Investor Event Today ,Timed Assessments ,Quantitative Myometry Testing ,Run Test ,Dystrophy Health Index ,Dystrophy Type ,Participation Scale ,North Star Ambulatory Assessment ,Drug Evaluation ,Myotonic Dystrophy Type ,Duchenne Muscular Dystrophy ,Private Securities Litigation Reform Act ,Clinical Update ,